



The natural course of a localized BCG vaccine abscess

Tobias Brummaier^{a,b,c,d,*}, Saw Poe Yen Yen^a, Daydaypoe Keereecharoen^a, Rose McGready^{a,d}, Michele Vincenti-Delmas^a

^a Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand

^b Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland

^c Faculty of Medicine, University of Basel, Basel, Switzerland

^d Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, United Kingdom



Fig. 1. (a) Initial presentation. (b) 1 week after initial presentation. (c) 4 weeks after initial presentation. (d) 10 weeks after initial presentation.

A mother presented her 1-month old term infant with a slowly progressive subcutaneous 1.2 by 1.2 cm swelling on the left upper arm (Fig. 1a). On the same site, 0.1 mL Bacille Calmette-Guérin (BCG) vaccine had been provided intradermally on the day of birth. Manufactured by Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok, Thailand (Lot No. FB00817), 1 mL contains about 2 million viable bacteria of the live attenuated *Mycobacterium bovis* Tokyo 172 strain. No systemic symptoms were reported and on examination, no lymphadenitis was present. A wait-and-see treatment approach was adopted, the infant was discharged home, and a local health care worker documented the spontaneous resolution of the lesion and the natural course of healing (Fig. 1b–d).

BCG vaccines have been used for nearly a century, are considered safe and remain recommended by a majority of countries [1]. Approximately 1–10% experience adverse reactions, of which most are localised (i.e. abscess, lymphadenitis); systemic adverse reactions (e.g. osteomyelitis, BCG disease) are rarely observed [2]. Adapting a conservative wait and see approach for localized BCG

injection site reactions as well as non-suppurative lymphadenitis, leads to a self-limiting, spontaneous resolution of symptoms in the majority of cases.

Acknowledgements

The Shoklo Malaria Research Unit is part of the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme supported by the Wellcome Trust of Great Britain.

References

- [1] Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics* 1995;96(1 Pt 1):29–35.
- [2] Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast AJ. Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions. *Vaccine* 2015;33(41):5470–4.

* Corresponding author.